Диссертация (1139911), страница 18
Текст из файла (страница 18)
Шурыгин М.Г., Шурыгина И.А., Дремина Н.Н. Каня О.В.Эндогенные прогениторы как источники клеточного материала длярепарации зоны ишемического повреждения при экспериментальноминфарктемиокардавусловияхизменениойконцентрациивазоэндотелиального фактора роста// Клеточные технологии в биологиии медицине -2014.-N 4.-С.212-215.107.Шутов A.M., Саенко Ю.В. Плеотропные кардиопротективныеэффекты эритропоэтина // Нефрология. – 2006. – Том 10(4).
– C.18-22.108. Юшков Б.Г., Климин В.Г., Арташян О.С. Тучные клетки игипоксия // Вестник Уральской медицинской академической науки. –2006. – N 1. – С.45-48109. Abdel-Latif A., Bolli R., Tleyjeh I.M, Montori V.M., Perin E.C.,Hornung C.A., Zuba-Surma E.K., Al-Mallah M., Dawn B. Adult bonemarrow-derived cells for cardiac repair: a systematic review and metaanalysis // Arch Intern Med.
– 2007. – May 28. – V.167(10). – P. 989-997.110. Alayat M.S., Elsodany A.M., El Fiky A.A. Efficacy of high and lowlevel laser therapy in the treatment of Bell's palsy: a randomized double blindplacebo-controlled trial // Lasers Med Sci. – 2014. – V. 29(1) . – P. 335-42.111. AlGhandi A., Kumar A., Moussa N.A. Low-level laser therapy: auseful technique for enhancing the proliferation of various cultured cells //Lasers Med. Sci. – 2012.
– V.27. – P. 237–249.112. Allakhverdi Z., Comeau M.R., Armant M., Agrawal R., Woodfolk J.A.,Sehmi R., Howie K.J., Gauvreau G.M., Delespesse G. Mast Cell-ActivatedBone Marrow Mesenchymal Stromal Cells Regulate Proliferation andLineage Commitment of CD34(+) Progenitor Cells // Front Immunol. – 2013.– V.4. – P.461-465.113. Alves A.N., Fernandes K.P., Deana A.M., Bussadori S.K., MesquitaFerrari R.A. Effects of Low-Level Laser Therapy on Skeletal Muscle Repair:A Systematic Review // Am J Phys Med Rehabil.–2014.–Aug 13.
[Epubahead of print]119114. Anwer A.G., Gosnell M.E., Perinchery S.M., Inglis D.W., Goldys E.M.Visible 532 nm laser irradiation of human adipose tissue-derived stem cells:effect on proliferation rates, mitochondria membrane potential andautofluorescence // Lasers Surg. Med. – 2012. – V.44. – P.769–778.115. Aoki A., Mizutani K., Takasaki A.A., Sasaki K.M., Nagai S.,Schwarz F., Yoshida I., Eguro T., Zeredo J.L., Izumi Y. Current status ofclinical laser applications in periodontal therapy // Gen Dent .–2008.–V.56(7).
– P. 674-687116. Asanuma H., Minamino T., Ogai A., Kim J., Asakura M., KomamuraK., Sanada S., Fujita M., Hirata A., Wakeno M., Tsukamoto O., Shinozaki Y.,Myoishi M., Takashima S., Tomoike H., Kitakaze M. Blockade of histamineH2 receptors protects the heart against ischemia and reperfusion injury indogs // J Mol Cell Cardiol. – 2006. – V.
40(5). – P. 666-74.117. Assmann A., Heke M., Kröpil P., Ptok L., Hafner D., Ohmann C.,Martens A., Karluβ A., Emmert M.Y., Kutschka I., Sievers H.H., Klein H.M.Laser-supportedCD133+celltherapyinpatientswithischemiccardiomyopathy: initial results from a prospective phase I multicenter trial //PLoS One. – 2014. – V. 9(7). – P. e101449.118. Azouz N.P., Fukuda M., Rothenberg M.E., Sagi-Eisenberg R.Investigating mast cell secretory granules; from biosynthesis to exocytosis // JVis Exp.
– 2015. – N. 95. – P.52505. doi: 10.3791/52505.119. Babin-Ebell J., Sievers H.H., Charitos E.I., Klein H.M., Jung F.,Hellberg A.K., Depping R., Sier H.A., Marxsen J., Stoelting S., Kraatz E.G.,Wagner K.F. Transmyocardial laser revascularization combined withintramyocardial endothelial progenitor cell transplantation in patients withintractableischemicheartdiseaseineligibleforconventionalrevascularization: preliminary results in a highly selected small patient cohort// Thorac Cardiovasc Surg. – 2010.
– V. 58(1). – P. 11-16.120. Baldwin A.L. Mast cell activation by stress.// Methods Mol Biol. –2006. – V. 315. – P. 349-360.120121. Bandara G., Metcalfe D.D., Kirshenbaum A.S. Growth of human mastcells from bone marrow and peripheral blood-derived CD34(+) pluripotenthematopoietic cells // Methods Mol Biol. – 2015. – V.1220. – P.155-162.122. Barboza C.A., Ginani F., Soares D.M., Henriques A.C., Freitas Rde A.Low-level laser irradiation induces in vitro proliferation of mesenchymal stemcells // Einstein (Sao Paulo). – 2014.
– V. 12(1). – P. 75-81.123. Bauer С. Erythropoietin – from gene structure to therapeuticapplications // J. Perinat. Med. – 1995. – V.23. – N 1–2. – Р.77–81.124. Bayat M., Vasheghani M.M., Razavie N., Jalili M.R. Effects of lowlevel laser therapy on mast cell number and degranulation in third-degreeburns of rats // J Rehabil Res Dev. 2008. – V. 45(6). – P. 931-938.125. Beaven M.A. Our perception of the mast cell from Paul Ehrlich to now// Eur J Immunol. 2009.
– V. 39(1). – P. 11-25.126. Beckmann K.H., Meyer-Hamme G., Schröder S. Low level lasertherapy for the treatment of diabetic foot ulcers: a critical survey // EvidBased Complement Alternat Med. – 2014. – V. 2014. – P. 626127.127. Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., ChimentiS., Kasahara H., Rota M., Musso E., Urbanek K., Leri A., Kajstura J., NadalGinard B., Anversa P. Adult cardiac stem cells are multipotent and supportmyocardial regeneration. // Cell.
– 2003. – V. 114(6). – P. 763-776.128. Bhattacharya K., Farwell K., Huang M., Kempuraj D., Donelan J.,Papaliodis D., Vasiadi M., Theoharides T.C. Mast cell deficient W/Wv micehave lower serum IL-6 and less cardiac tissue necrosis than their normallittermates following myocardial ischemia-reperfusion // Int J ImmunopatholPharmacol. –2007. – V. 20. – P. 69–74.129. Bidri M. Nitric oxide pathway is induced by Fc epsilon RI and upregulated by stem cell factor in mouse mast cells / M. Bidri, S. Ktorza, I.Vouldoukis [et al] // Eur J Immunol. – 1997. – V.27, N11.
– P.2907-2913.121130. Bidri M., Féger F., Varadaradjalou S., Ben Hamouda N., GuillossonJ.J., Arock M. Mast cells as a source and target for nitric oxide // IntImmunopharmacol. – 2001. – V.1(8). – P.1543-1558.131. Bjordal J.M., Bensadoun R.-J., Tuner J., Frigo L., Gjerde K., LopesMartins R.A. A systematic review with meta-analysis of the effect of lowlevel laser therapy (LLLT) in cancer therapy-induced oral mucositis //Support. Care Cancer. – 2011. – V.19. – P.1069–1077.132. Bolli R., Chugh A.R., D'Amario D., Loughran J.H., Stoddard M.F.,Ikram S., Beache G.M., Wagner S.G., Leri A., Hosoda T., Sanada F., ElmoreJ.B., Goichberg P., Cappetta D., Solankhi N.K., Fahsah I., Rokosh D.G.,Slaughter M.S., Kajstura J., Anversa P. Cardiac stem cells in patients withischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1trial.
// Lancet. – 2011. – V. 378(9806). – P. 1847-57.133. Bolli R., Tang X.L., Sanganalmath S.K., Rimoldi O., Mosna F., AbdelLatif A., Jneid H., Rota M., Leri A., Kajstura J. Intracoronary delivery ofautologous cardiac stem cells improves cardiac function in a porcine model ofchronic ischemic cardiomyopathy // Circulation. – 2013. – V. 128(2).
– P.122-131.134. Brenner W., Aicher A., Eckey T., Massoudi S., Zuhayra M., Koehl U.,et al. 111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardialinfarction model // J Nucl Med 2004. – V. 45(3). – P. 512–518.135. Brooks A.C. Reactive oxygen species generation and histamine releaseby activated mast cells: modulation by nitric oxide synthase inhibition / A.C.Brooks, C.J. Whelan, W.M. Purcell // British Journal of Pharmacology.
–1999. – V.128. – P.585-590.136. Brower G.L., Chancey A.L., Thanigaraj S., Cause and effectrelationship between myocardial mast cell number and matrixmetalloproteinase activity. //Am J Physiol Heart Circ Physiol.-2002.283:518–H525.122137. Bullard A.J., Yellon D.M. Chronic erythropoietin treatment limitsinfarct-size in the myocardium in vitro // Cardiovasc Drugs Ther.
– 2005. –V. 19(5). – P. 333-336138. Carlos D. Histamine modulates mast cell degranulation through anindirect mechanism in a model IgE-mediated reaction / D. Carlos, A. SáNunes, L. de Paula // Eur J Immunol. – 2006. – V.36, N6. – P.1494-1503.139. Carmeliet P., Moons L., Lijnen R., et al. Urokinase-generated plasminactivates matrix metalloproteinases during aneurysm formation. //Nat Genet.1997.-17:439–444.140. Chancey A.L., Gardner J.D., Murray D.B., et al.Modulation of cardiacmast mediated extracellular matrix degradation by estrogen.// Am J PhysiolHeart Circ Physiol.- 2005.-289:H316–H321141.
Chow R.T., Johnson M.I., Lopes-Martins R.A., Bjordal J.M. Efficacyof low-level laser therapy in the management of neck pain: a systematicreviewand meta-analysis ofrandomisedplacebooractive-treatmentcontrolled trials // Lancet. – 2009. – V. 374(9705). – P. 1897-908.142. Chugh A.R., Beache G.M., Loughran J.H., Mewton N., Elmore J.B.,Kajstura J., Pappas P., Tatooles A., Stoddard M.F., Lima J.A., SlaughterM.S., Anversa P., Bolli R. Administration of cardiac stem cells in patientswith ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interimanalysis of myocardial function and viability by magnetic resonance. //Circulation.
– 2012. – V. 126(11 Suppl 1). – P. S54-64.143. Coleman J.W. Nitric oxide: a regulator of mast cell activation and mastcell-mediated inflammation / J.W. Coleman // Clin Exp Immunol. – 2002. –V.129. – P.4-10.144. Crivellato E., Beltrami C.A., Mallardi F., Ribatti D. The mast cell: anactive participant or an innocent bystander? // Histol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
